November 16, 2016 - By Vivian Park · 0 Comments
Stereotaxis Inc (OTCMKTS:STXS) institutional sentiment increased to 1.5 in 2016 Q2. Its up 0.61, from 0.89 in 2016Q1. The ratio is better, as 9 funds started new or increased stock positions, while 6 sold and decreased their positions in Stereotaxis Inc. The funds in our partner’s database now possess: 3.33 million shares, up from 3.19 million shares in 2016Q1. Also, the number of funds holding Stereotaxis Inc in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 5 Reduced: 1 Increased: 6 New Position: 3.
Stereotaxis, Inc. is a United States healthcare technology company. The company has a market cap of $13.14 million. The Firm is engaged in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease. It currently has negative earnings. The Firm also provides information management solutions for the interventional lab.
The stock increased 17.65% or $0.09 on November 15, hitting $0.6. About 263,914 shares traded hands or 170.89% up from the average. Stereotaxis Inc (OTCMKTS:STXS) has declined 65.91% since April 14, 2016 and is downtrending. It has underperformed by 70.60% the S&P500.
According to Zacks Investment Research, “Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to allow physicians to navigate catheters, guidewires and stent delivery devices through the blood vessels and chambers of the heart to treatment sites.”
Dafna Capital Management Llc holds 1.07% of its portfolio in Stereotaxis Inc for 1.37 million shares. Perkins Capital Management Inc owns 23,000 shares or 0.03% of their US portfolio. Moreover, Two Sigma Securities Llc has 0.01% invested in the company for 16,413 shares. The North Carolina-based Bank Of America Corp De has invested 0% in the stock. Blackrock Fund Advisors, a California-based fund reported 5,202 shares.#img1#
Stereotaxis, Inc., incorporated on June 13, 1990, designs, makes and markets robotic systems and instruments for use by electrophysiologists for the treatment of abnormal heart rhythms known as cardiac arrhythmias. The Firm offers its Epoch Solution, a remote robotic navigation system for use in a hospital’s interventional surgical suite or interventional lab. The Epoch Solution consists of the Niobe ES Robotic Magnetic Navigation System (Niobe ES system), Odyssey Information Management Solution (Odyssey Solution) and the Vdrive Robotic Navigation System (Vdrive system), and related devices.
More important recent Stereotaxis Inc (OTCMKTS:STXS) news were published by: Thestreet.com which released: “Stereotaxis (STXS) Stock Soars Today After FDA Clears Vdrive for Market Entry” on January 05, 2015, also Globenewswire.com published article titled: “U.S. Hospital Surpasses 1000 Procedures using Stereotaxis Niobe® System”, Seekingalpha.com published: “Stereotaxis: A Good Opportunity For Risk-Tolerant Investors” on August 16, 2013. More interesting news about Stereotaxis Inc (OTCMKTS:STXS) was released by: Bizjournals.com and their article: “Stereotaxis secures $24 million in equity financing” with publication date: September 27, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Vivian Park